News
The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still ...
The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.
Moderna’s mRNA flu shot outperforms existing vaccines in Phase 3 trial, showing over 26% greater efficacy—paving the way for ...
RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...
In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...
Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...
22h
Clinical Trials Arena on MSNModerna’s mRNA flu shot outperforms current standard at Phase IIIThe trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.
Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...
If we don’t invest in technologies like mRNA vaccines for pandemic influenza now, once a virus starts going human-to-human, ...
Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose ...
Moderna's flu vaccine candidate, mRNA-1010, shows 26.6% efficacy in a Phase 3 trial for adults 50+. Read more here.
The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review standards.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results